drugset / Trial / NCT00326144

Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders

NCT00326144

Phase 3 Completed 310 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to demonstrate superior efficacy of Quetiapine fumarate sustained release (SEROQUEL) compared with placebo when used as a mono-therapy in the treatment of Major Depressive Disorders PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Timeline

Start
2006-04
Primary completion
Completion
2007-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 150 mg
Subject Quetiapine Small molecule 300 mg